SCHEMBL2999105

SCHEMBL2999105

Cc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4ccccc4Br)CC3)n2)c1C

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.44
MAPT P10636 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 1/20 0.43
GBA1 P04062 3/20 0.41
PKM P14618 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TP53 P04637 1/20 0.38
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014384 0.93 GBA1 (0.43) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL3018789 0.90 MEN1 (0.45) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL3008342 0.89 LMNA (0.44) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL3013687 0.87 KMT2A (0.42) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL3014380 0.86 KMT2A (0.48) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL3014121 0.86 ALDH1A1 (0.46) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL3008380 0.86 ALDH1A1 (0.42) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL3013921 0.86 SMN1; SMN2 (0.46) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL3012131 0.85 TP53 (0.40) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL3012730 0.85 CTSS (0.39) LMNAMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPT 18/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.